Lipella Pharmaceuticals Announced U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Benzinga · 10/15 09:09

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The patent application, U.S. Patent No. 17/829,960, titled "Delivery of Agents Using Metastable Liposomes," covers key innovations in Lipella's platform technology for delivering therapeutic agents via liposome-based vehicles.